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Hemophagocytic syndrome (HS) is a clinico-patho-
logic entity characterized by activation and
uncontrolled non-malignant proliferation of T lym-
phocytes and macrophages. This syndrome, more
properly referred to as hemophagocytic lymphohis-
tiocytosis (HLH), is a rare disorder of infancy and
early childhood.1,2 The association of HLH and visc-
eral leishmaniasis (VL) is only rarely found in adults
and, when VL and HLH present together in patients,
diagnosis of the disease may be difficult.2,3 Herein,
we describe a case of HLH as a complication of VL.
A 34-year-old man was admitted to the Depart-
ment of Infectious Diseases at Rabta Hospital, Tunis,
in May 2003 with a 4-week history of progressive
fever accompanied by a marked alteration in his
general health, fever, chills, sweats and diarrhea.
On physical examination he was found to be febrile
(39 8C) and pale. He had hepatomegaly and spleno-
megaly, but lymph nodes were not enlarged. His
vital signs were normal and the rest of the physical
examination was unremarkable.
His white blood cell count was 1.89  109/L with
lymphopenia, anemia and thrombopenia (platelet
count, 45  109/L). Serum triglycerides were incr-
eased to 267 mg/dl with normal cholesterol, and the
serum lactate dehydrogenase level was elevated at
1572 U/L. Liver function tests showed alanine
amino-transferase (ALT) at 109 U/L and aspartate
amino-transferase (AST) at 413 U/L, with alkaline
phosphatase at 1169 U/L, and a raised total bilirubin
of 17 mg/dl. There was no serological evidence of
infection with cytomegalovirus, Epstein—Barr virus
or toxoplasmosis. Cultures of blood were negative
for specific bacteria. HIV status was unknown
because of the fulminant course of the disease.Initially, the patient received treatmentwith anti-
biotics (cefotaxime and ofloxacin), but he continued
to have fever with gastrointestinal bleeding and
severepancytopenia, anddisseminated intravascular
coagulation was diagnosed. The bone marrow aspi-
rate was normal, and bone marrow culture for para-
sites was negative. However, peripheral blood
culture for parasites yielded Leishmania infantum,
identified as Zymodeme MON 1 at the reference
center for leishmaniasis in Montpellier, France.
The patient’s condition worsened and he died 2
days later from acute gastrointestinal hemorrhage.
Bone marrow biopsy performed after death showed
increased monohistiocytes containing phagocytosed
erythrocytes, lymphocytes and leukocytes, but no
malignancy. These findings, together with clinical
presentation and laboratory data, were compatible
with a diagnosis of hemophagocytic syndrome. Post
mortem findings of liver biopsy showed extensive
necrosis with steatohepatitis.
To our knowledge, this is the first report of HLH
associatedwith VL in adults in Tunisia. The diagnostic
criteria ofHLHproposedby theFHL studygroupof the
Histiocyte Society in 1991,4 include clinical, labora-
tory, andhistopathologic features. Themost common
signs are fever and splenomegaly, but hepatomegaly,
lymphadenopathy, jaundice, rash and central ner-
vous systemmanifestations are also seen. Laboratory
abnormalities include pancytopenia associated with
hypofibrinogenemia, and elevated circulating fibrin
degradation products. Most patients have hypertri-
glyceridemia, elevation of lactate dehydrogenase
and marked elevation of ferritin.1,4
Histopathologically, hemophagocytosis is seen in
bone marrow, spleen, lymph nodes, and occasionally
the central nervous system and skin. Our patient had
an abnormal coagulation profile, elevated liver
enzyme activities, high triglyceride levels, low
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gocytosis, in keeping with diagnostic criteria of HLH.
Among the numerous causes of reactive hemo-
phagocytic processes, the main ones are lymphomas
and viral infections.3 The first case of VL revealed by
a reactive HLH was reported in an adult patient by
Matzner et al.5 The diagnosis of VL may be difficult
as clinical signs are similar in both VL and HLH.
Furthermore, serologic testing for Leishmania may
be negative at the onset of the disease.1 In a
recently reported French series of VL,6 the parasite
was not detected in 22% of cases. The reason for the
parasite scarcity in BM smears of patients with VL-
associated HLH is unclear. For our patient, Leishma-
nia was isolated only in peripheral blood culture,
and BM aspirate was negative for parasites at direct
microscopic examination and culture. Thus, diag-
nostic delays played an important role in the pro-
gressive fatal course of our patient’s disease.
Several therapeutic protocols are proposed in
HLH and depend on the type of hemophagocytic
syndrome. In reactive HLH associated with infec-
tion, supportive care and specific treatment of the
infection are associated with recovery in 60—70% of
cases.7 Thus, the causal therapy of leishmaniasis-
associated HLH is based on pentavalent antimonials
or amphotericin B, with corticosteroids.2
Liposomal amphotericin B seems most suitable
for VL-associated HLH, because lipid-associated
amphotericin B is taken up by macrophages and
targets the drug to the site of infection, leading
to very high concentration in the liver and spleen.1
Others drugs have been used when HLH is asso-
ciated with infectious disorders, such as intravenous
immunoglobulin, etoposide (which is cytotoxic
for macrophages), interferon alpha, corticoids,
thalidomide, cyclosporin, cyclophosphamide and
antilymphocyte serum.7
In conclusion, diagnosis of VL may be difficult,
when it is associated with hemophagocytosis.
Therefore, leishmaniasis should be considered when
discussing the cause of HLH in countries where the
disease is endemic, such as Tunisia. Early diagnosis
and appropriate treatment of VL are mandatory in
order to improve prognosis.
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23 June 2004Coccidioidal pericarditis
We recently presented a case report and review of
the literature concerning coccidioidal pericarditis
(CP).1 In all, 17 cases were described. During
the time between acceptance of this report andpublication an additional patient with CP has been
detailed and we believe it would be worthwhile to
highlight this case.
A 10 year-old African American girl presented
with chest discomfort and dyspnea. She was found
to have a left-sided pulmonary infiltrate and a large
